Patiromer: a clinical review

References

• Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit; a clinical review. Am J Health Syst Pharm 2005;62:1663-82
   PubMed Web of Science ®Google Scholar
• Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169: 1156-62
   PubMed Web of Science ®Google Scholar
• Ingelfinger JR. Editorial: a new era for the treatment of hyperkalemia? N Engl J Med 2015;372:275-8
   PubMed Web of Science ®Google Scholar
• Ahuja TS, Freeman D, Mahnken JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000;20:268-72
   PubMed Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system. N Engl J Med 2004;351:585-92
   PubMed Web of Science ®Google Scholar
• Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. J Am Med Assoc 2009;302:1658-65
   PubMed Web of Science ®Google Scholar
• Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don’t: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol 2010;5:1723-6
   PubMed Web of Science ®Google Scholar
• Kayexalate [package insert]. Bridgewater, NJ: Sanofi-aventis US LLC, 2010
   Google Scholar
• McCullough PA, Beaver TM, Bennett-Guerrero E, et al. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med 2014;15:11-23
   PubMed Web of Science ®Google Scholar
• Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci 2014;347:93-100
   PubMed Web of Science ®Google Scholar
• Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron 2002;92(Suppl 1):33-40
   PubMed Web of Science ®Google Scholar
• Rastergar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J 2001;77:759-64
   PubMed Web of Science ®Google Scholar
• Nasir K, Ahmad A. Treatment of hyperkalemia in patients with chronic kidney disease: a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate. J Ayub Med Coll Abbottabad 2014;26:455-8
   PubMedGoogle Scholar
• Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report. N Engl J Med 1961;264:111-15
   PubMed Web of Science ®Google Scholar
• Lillemoe KD, Romolo JL, Hamilton SR, et al. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery 1987;101:267-72
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Kayexalate (sodium polystyrene sulfonate) powder. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). September 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/011287s022ltr.pdf [Last accessed 15 June 2015]
   Google Scholar
• Winkelmayer WC. Editorial: treatment of hyperkalemia from ‘Hyper K+’ strikeout to home run? J Am Med Assoc 2015;314:129-30
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372:211-21
   PubMed Web of Science ®Google Scholar
• Buysse JM, Huang ZI, Pitt B. Clinical trial commentary, PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012;8:17-28
   PubMedGoogle Scholar
• Bushinsky DA, Bakris GL, Williams G, et al. Patiromer induced a rapid onset of action and sustained potassium lowering throughout the treatment period in CKD patients with hyperkalemia. Poster (SA-PO153) presented at the American Society of Nephrology’s 2014 Kidney Week, 11–16 November 2014, Philadelphia, PA, USA. Provided by Relypsa Inc
   Google Scholar
• Pitt B, Mayo M, Garza D, et al. Serum potassium reduction and prevention of recurrent hyperkalemia with patiromer in patients with heart failure and chronic kidney disease on RAAS Inhibitors. Oral PowerPoint presented at the 18th Annual Scientific Meeting for the Heart Failure Society of America, September 2014, Las Vegas, NV, USA
   Google Scholar
• Epstein M, Palmer B, Mayo M, et al. Mechanism of action of patiromer for oral suspension: Increases fecal K+ excretion in healthy subjects independent of race. Poster presented at the 2015 World Congress of Nephrology, 14 March 2015, Cape Town, South Africa. Available at: http://www.abstracts2view.com/wcn/view.php?nu=WCN15L_SAT-218 [Last accessed 22 June 2015]
   Google Scholar
• Wheeler S. Relypsa announces key data presented at ASN on long-term chronic treatment and early onset of action with patiromer for oral suspension. Relypsa. 4 November 2014. Available at: http://investor.relypsa.com/releasedetail.cfm?ReleaseID=883262 [Last accessed 22 June 2015]
   Google Scholar
• Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32:820-8
   PubMed Web of Science ®Google Scholar
• Weir M, Bakris G, Gross C, et al. Patiromer decreases aldosterone with decreases in urine albumin/creatinine ratio and systolic blood pressure in patients with chronic kidney disease and hyperkalemia on RAAS inhibitors: results from OPAL-HK. Poster (LB1) presented at the American Society of Hypertension Annual Scientific Meeting, May 2015, New York, NY, USA
   Google Scholar
• Slomski A. Hyperkalemia controlled with 2 novel medications. J am Med Assoc 2015;313:347
   Web of Science ®Google Scholar
• Weir M, Bushinsky D, Mayo M, et al. Patiromer reduced recurrent hyperkalemia in patients with advanced CKD on RAAS inhibitors: results from the randomized phase 3 OPAL-HK study. Poster (240) presented at the National Kidney Foundation Spring Clinical Meeting, March 2015, Dallas, TX, USA
   Google Scholar
• Weir M, Bakris G, Mayo M, et al. Patiromer increased time to renin–angiotensin–aldosterone system inhibitor discontinuation compared with placebo in advanced chronic kidney disease patients with hyperkalemia: results from the randomized phase 3 OPAL-HK study. Poster (P87) presented at the American Society of Hypertension Annual Scientific Meeting, May 2015, New York, NY, USA
   Google Scholar
• AMETHYST-DN. RLY5016 in the treatment of hyperkalemia in patients with hypertension and diabetic nephropathy. Available at: https://clinicaltrials.gov/ct2/show/record/NCT01371747?term=amethyst-dn&rank=1. NLM identifier: NCT01371747 [Last accessed 22 June 2015]
   Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. J Am Med Assoc 2015;314:151-61
   PubMed Web of Science ®Google Scholar
• Bakris G, Pitt B, Mayo M, et al. Reduction of serum K+ with patiromer for 1 year with diabetic CKD who developed hyperkalemia while on maximal losartan and/or spironolactone. J Am Soc Hypertens 2015;9:e75-283
   Google Scholar
• Bakris G, Pitt B, Weir M, et al. Reduction of serum K+ with patiromer for 1 year in patients with diabetic CKD who developed hyperkalemia while on maximal losartan and/or spironolactone. Poster (P126) presented at American Society of Hypertension 2015 Annual Scientific Meeting, May 2015, New York, NY, USA
   Google Scholar
• Pitt B, Bakris G, Weir M, et al. 1-year safety and efficacy of patiromer for the treatment of hyperkalemia in patients with heart failure and chronic kidney disease on renin-angiotensin-aldosterone system inhibitors: results from AMETHYST-DN. Poster (1145-184) presented at the American College of Cardiology, March 2015, San Diego, CA, USA
   Google Scholar
• Pitt B, Bushinsky D, Garza D, et al. 1-year safety and efficacy of patiromer for hyperkalemia in heart failure patients with chronic kidney disease on renin–angiotensin–aldosterone system inhibitors. J Am Coll Cardiol 2015;65:A855
   Web of Science ®Google Scholar
• Bakris G, Pitt B, Weir M, et al. Sodium, potassium and blood pressure. Nephrology Dialysis Transplant 2015;30(Suppl 3):iii51-2
   Google Scholar
• Bakris G, Pitt B, Mayo M, et al. Effect of patiromer on hyperkalemia in patients with diabetic nephropathy: results of a 1-year randomized trial (AMETHYST-DN). Poster (SA-PO1099) presented at the American Society of Nephrology’s 2014 Kidney Week, 11–16 November 2014, Philadelphia, PA, USA. Provided by Relypsa, Inc
   Google Scholar
• Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45
   PubMed Web of Science ®Google Scholar
• Molnar MZ, Kalantar-Zadeh K, Lott EH, et al. ACE inhibitor and angiotensin receptor blocker use and mortality in patients with chronic kidney disease. J Am Coll Cardiol 2014;63:650-8
   PubMed Web of Science ®Google Scholar
• Arroyo D, Panizo N, Garcia de Vinuesa S, et al. Hypercalcemia as a side effect of potassium binding agents. Nefrologia 2012;32:655-8
   PubMed Web of Science ®Google Scholar